Authors
Latest:
Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMDDr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
Latest:
Ultra-widefield imaging can enhance efficiency for practicesPhysicians can discover, diagnose, document, treat diseases that might go undetected
Latest:
Noninfectious uveitis: Meeting the challengeChronic cases can be difficult for retina specialists; treatment is satisfying.
Latest:
Achieving high-definition slit lamp imaging via smartphone mirroringThis affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.
Latest:
Satellite clinics and other strategies to enhance rural ophthalmologyProactive communication and leveraging advanced, yet reliable, technologies to maximize efficiency are essential pillars of success.
Latest:
The future of retina careRetina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Latest:
Investigating the quality of real-world evidence in retinal diseaseReal-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Latest:
Precision medicine in diabetic macular edema: Expert consensus on the efficacy and safety of the 0.19-mg fluocinolone acetonide implantResults from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.
Latest:
Dexamethasone rebuttal: Who should perform intravitreal injections?In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Latest:
AAO 2024: Fundus photography/OCT expediates care in the emergency departmentValerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the on-call ophthalmologists.
Latest:
Sustained drug delivery in ophthalmologyCurrent options, challenges in developing novel therapies.
Latest:
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic AtrophyA retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
Latest:
FDA issues CRL for aflibercept 8 mg from Regeneron PharmaceuticalsThe company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Latest:
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMDDr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Latest:
UNCOVERING HIDDEN PREDATORS IN DISEASEThis article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Latest:
Natural language processing helps ophthalmologists access data, improves data curationKnowledge of tools used in data interpretation helps clinicians trust accuracy of findings.
Latest:
Latest tech trends to benefit patients with AMDTechnology brings new tools to those with low vision caused by AMD
Latest:
Overcoming the wet AMD treatment gapA key distinction between patients seen in the clinic vs those enrolled in clinical trials has to do with characteristics dictated by the trial’s inclusion/exclusion criteria.
Latest:
Successful ocular surgery in patients with chronic uveitisWhile operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
Latest:
Promoting Treatment Adherence in nAMD and DMEExperts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.
Latest:
Is complement therapy the path forward for geographic atrophy?Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
Latest:
US FDA issues approval for two aflibercept biosimilarsThe agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).
Latest:
Adapting medical retina service in COVID-19 era requires careful approachMinimizing clinic visits, maximizing use of imaging modalities are key
Latest:
ABVC BioPharma announces approved plan for pilot Good Manufacturing Practice (GMP) facility to produce VitargusThe plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
